JP5259896B2 - 増殖性疾患を治療するための抗プロラクチン剤の使用 - Google Patents

増殖性疾患を治療するための抗プロラクチン剤の使用 Download PDF

Info

Publication number
JP5259896B2
JP5259896B2 JP2000547993A JP2000547993A JP5259896B2 JP 5259896 B2 JP5259896 B2 JP 5259896B2 JP 2000547993 A JP2000547993 A JP 2000547993A JP 2000547993 A JP2000547993 A JP 2000547993A JP 5259896 B2 JP5259896 B2 JP 5259896B2
Authority
JP
Japan
Prior art keywords
hprl
cells
prl
prolactin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000547993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515404A (ja
JP2002515404A5 (enExample
Inventor
ウェン ワイ． シェン
トーマス イー． ワグナー
Original Assignee
オンコリクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26772335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5259896(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オンコリクス インコーポレイテッド filed Critical オンコリクス インコーポレイテッド
Publication of JP2002515404A publication Critical patent/JP2002515404A/ja
Publication of JP2002515404A5 publication Critical patent/JP2002515404A5/ja
Application granted granted Critical
Publication of JP5259896B2 publication Critical patent/JP5259896B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000547993A 1998-05-12 1999-05-11 増殖性疾患を治療するための抗プロラクチン剤の使用 Expired - Lifetime JP5259896B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US60/085,128 1998-05-12
US24604199A 1999-02-05 1999-02-05
US09/246,041 1999-02-05
PCT/US1999/010232 WO1999058142A1 (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010223963A Division JP2011079821A (ja) 1998-05-12 2010-10-01 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2011149371A Division JP5453355B2 (ja) 1998-05-12 2011-07-05 増殖性疾患を治療するための抗プロラクチン剤の使用

Publications (3)

Publication Number Publication Date
JP2002515404A JP2002515404A (ja) 2002-05-28
JP2002515404A5 JP2002515404A5 (enExample) 2011-08-25
JP5259896B2 true JP5259896B2 (ja) 2013-08-07

Family

ID=26772335

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000547993A Expired - Lifetime JP5259896B2 (ja) 1998-05-12 1999-05-11 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2010223963A Withdrawn JP2011079821A (ja) 1998-05-12 2010-10-01 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2011149371A Expired - Lifetime JP5453355B2 (ja) 1998-05-12 2011-07-05 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2013127119A Withdrawn JP2013224309A (ja) 1998-05-12 2013-06-18 増殖性疾患を治療するための抗プロラクチン剤の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010223963A Withdrawn JP2011079821A (ja) 1998-05-12 2010-10-01 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2011149371A Expired - Lifetime JP5453355B2 (ja) 1998-05-12 2011-07-05 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2013127119A Withdrawn JP2013224309A (ja) 1998-05-12 2013-06-18 増殖性疾患を治療するための抗プロラクチン剤の使用

Country Status (11)

Country Link
US (2) US7115556B2 (enExample)
EP (2) EP1079851B1 (enExample)
JP (4) JP5259896B2 (enExample)
AT (1) ATE366114T1 (enExample)
AU (1) AU3895299A (enExample)
CA (1) CA2328520C (enExample)
DE (1) DE69936451T2 (enExample)
DK (1) DK1079851T3 (enExample)
ES (1) ES2288777T3 (enExample)
PT (1) PT1079851E (enExample)
WO (1) WO1999058142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404088A1 (en) * 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
US7820146B2 (en) * 2002-06-12 2010-10-26 L'oreal S.A. Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form
AU2003300904A1 (en) 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2008114077A1 (en) * 2007-03-20 2008-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active mutants of the prolactin receptor
EP2167116A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2009135056A2 (en) * 2008-04-30 2009-11-05 Monsanto Technology Llc Recombinant dna vectors for expression of human prolactin antagonists
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
AU2010218261B2 (en) * 2009-02-26 2015-08-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8759289B2 (en) * 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) * 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
ES2180571T3 (es) 1993-02-19 2003-02-16 Genentech Inc Antagonistas de ligando para el tratamiento de cancer de mama.
PT754682E (pt) * 1994-04-06 2002-03-28 Nippon Shinyaku Co Ltd Derivado de aminostilbazol e medicamento
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JP2013224309A (ja) 2013-10-31
US20030022833A1 (en) 2003-01-30
PT1079851E (pt) 2007-10-08
WO1999058142A1 (en) 1999-11-18
JP2002515404A (ja) 2002-05-28
WO1999058142A9 (en) 2000-02-10
EP1079851A1 (en) 2001-03-07
CA2328520C (en) 2013-06-25
DE69936451T2 (de) 2008-03-13
JP2012020996A (ja) 2012-02-02
US20070060520A1 (en) 2007-03-15
EP1079851A4 (en) 2004-03-17
AU3895299A (en) 1999-11-29
EP1079851B1 (en) 2007-07-04
US7115556B2 (en) 2006-10-03
ES2288777T3 (es) 2008-01-16
DE69936451D1 (de) 2007-08-16
JP5453355B2 (ja) 2014-03-26
JP2011079821A (ja) 2011-04-21
DK1079851T3 (da) 2007-09-24
EP2316467A1 (en) 2011-05-04
CA2328520A1 (en) 1999-11-18
ATE366114T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
JP5453355B2 (ja) 増殖性疾患を治療するための抗プロラクチン剤の使用
Chen et al. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis
Yamada et al. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action
JP4142743B2 (ja) 副甲状腺ホルモンに関連する新規ペプチド類似体
JP2022180637A (ja) 疾患の治療のための改変されたミュラー管抑制物質（ｍｉｓ）タンパク質およびその使用
JP2004002440A (ja) 腫瘍転移防止用組成物
AU2007255419A1 (en) Stabilized insulin-like growth factor polypeptides
Talamantes et al. Beyond carrier proteins. Structure and regulation of expression of the mouse GH receptor
Lehmann et al. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor
US8754031B2 (en) Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
WO1999058097A2 (en) Use of anti-prolactin agents to treat proliferative conditions
EP1908475A1 (en) Use of anti-prolactin agents to treat cancer
HK1117764A (en) Use of anti-prolactin agents to treat cancer
HK1157629A (en) Use of a prolactin variant for treating cancer
US20240325501A1 (en) Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity
WO2001036446A2 (en) Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases
Goffin et al. Development of prolactin receptor antagonists: same goal, different ways
Suzuki Parathyroid hormone-related protein
Flynn et al. A mutant receptor with enhanced dominant-negative activity for the blockade of human prolactin signalling
Jensen et al. Bradykinin receptors in the gastrointestinal tracts of trout and cod: Evidence for a novel type of receptor
Kline Modulation of tension in Iguana iguana aortic rings by calcitonin gene-related peptide (CGRP)
Hirai et al. cDNA cloning of GTH receptor family from ovaries of the starfish Asterina pectinifera
Reuben et al. Developmental profile of the ecdysone receptor mediating salivary gland degeneration in an ixodid tick (Acari: Ixodidae)
Yamada et al. Articles in PresS. Am J Physiol Cell Physiol (March 11, 2009). doi: 10.1152/ajpcell. 00598.2008
Lin The nuclear actions of IGFBP-3

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100129

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100310

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110412

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110705

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130425

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160502

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term